أعرض في EDS

A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer

التفاصيل البيبلوغرافية
العنوان: A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer
المؤلفون: Karim Fizazi, Laurence Collette, Jean-Pierre Pignon, Chris Parker, Sigbjørn Smeland, Safae Terrisse, Karamouza Eleni, A. Oliver Sartor, Gwénaël Le Teuff, Nicholas D. James, Sarah Pirrie, Bertrand F. Tombal, Jad Chahoud, Bjørn Erisktein
المصدر: Journal of Clinical Oncology. 36:352-352
بيانات النشر: American Society of Clinical Oncology (ASCO), 2018.
سنة النشر: 2018
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Hazard ratio, medicine.disease, law.invention, Prostate cancer, Bone targeting, Randomized controlled trial, law, Internal medicine, Meta-analysis, medicine, External beam radiotherapy, Radio isotopes, business
الوصف: 352 Background: Among bone-targeted radio-isotopes (RI), Radium-223 (an α-emitter) is the only one with clearly demonstrated overall survival (OS) benefit in men with castration-resistant prostate cancer (CRPC). The aim of this meta-analysis is to estimate the OS impact of RI in men with CRPC. Methods: An individual patient data meta-analysis was carried out from randomized trials with inclusion period 1993-2013. Eligible trials included more than 50 patients, mandated bone metastases from CRPC and randomly evaluated RI. Endpoints were OS (primary), symptomatic skeletal events (SSE) and toxicity. A fixed-effect model was used. The log-rank test stratified by trial was used to estimate individual and overall hazard ratios (HR). Subset analyses were performed by the type of radiation (α vs. β emission) and by trial comparison: RI + Chemotherapy (CT) vs. CT, RI+ External beam radiotherapy (EBRT) vs. EBRT, RI vs. EBRT. Results: From 9 identified trials, data from 6 trials comprising 2081 patients (min: 64, max: 921) were collected with 2 trials representing 80% of data. The data from 3 trials (n = 341) were not available. The overall effect on OS favoured RI with HR = 0.86 [0.77-0.95] but high heterogeneity between trials (p < 0.001, I2= 79.6%). The overall effect of α- emitters on OS (HR = 0.70 [0.58; 0.83], 2 trials, n = 985) significantly differed from that of β-emitters (HR = 0.96 [0.84; 1.10], n = 4 trials, n = 1096) (interaction p = 0.0041). The overall effect on SSE favoured RI with HR = 0.81 [0.69-0.93] (4 trials, n = 1806) with marked between trial heterogeneity (p = 0.08, I² = 55.3%) and a significant difference (p = 0.02) by the type of RI (α-emitters: HR = 0.65 [0.52-0.82]-2 trials, β-emitters: HR = 0.93 [0.77-1.13]-2 trials). Conclusions: In men with metastatic CRPC a significant improvement of OS and SSE was obtained with bone targeted α-emitter radio isotopes, but not with β-emitter. However, some between trial heterogeneity of effects on OS need further investigations.
تدمد: 1527-7755
0732-183X
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dafb509e72475258704096d825d8b0f4Test
https://doi.org/10.1200/jco.2018.36.6_suppl.352Test
رقم الانضمام: edsair.doi...........dafb509e72475258704096d825d8b0f4
قاعدة البيانات: OpenAIRE
ResultId 1
Header edsair
OpenAIRE
edsair.doi...........dafb509e72475258704096d825d8b0f4
793
3

unknown
793.350158691406
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........dafb509e72475258704096d825d8b0f4&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Karim+Fizazi%22&quot;&gt;Karim Fizazi&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Laurence+Collette%22&quot;&gt;Laurence Collette&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jean-Pierre+Pignon%22&quot;&gt;Jean-Pierre Pignon&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chris+Parker%22&quot;&gt;Chris Parker&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sigbj&#248;rn+Smeland%22&quot;&gt;Sigbj&#248;rn Smeland&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Safae+Terrisse%22&quot;&gt;Safae Terrisse&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Karamouza+Eleni%22&quot;&gt;Karamouza Eleni&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22A%2E+Oliver+Sartor%22&quot;&gt;A. Oliver Sartor&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gw&#233;na&#235;l+Le+Teuff%22&quot;&gt;Gw&#233;na&#235;l Le Teuff&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nicholas+D%2E+James%22&quot;&gt;Nicholas D. James&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sarah+Pirrie%22&quot;&gt;Sarah Pirrie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bertrand+F%2E+Tombal%22&quot;&gt;Bertrand F. Tombal&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jad+Chahoud%22&quot;&gt;Jad Chahoud&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bj&#248;rn+Erisktein%22&quot;&gt;Bj&#248;rn Erisktein&lt;/searchLink&gt; )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt;. 36:352-352 )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => American Society of Clinical Oncology (ASCO), 2018. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2018 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Oncology%22&quot;&gt;Oncology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cancer+Research%22&quot;&gt;Cancer Research&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Emedical%5Fspecialty%22&quot;&gt;medicine.medical_specialty&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Chemotherapy%22&quot;&gt;Chemotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22business%2Eindustry%22&quot;&gt;business.industry&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Emedical%5Ftreatment%22&quot;&gt;medicine.medical_treatment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hazard+ratio%22&quot;&gt;Hazard ratio&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%2Edisease%22&quot;&gt;medicine.disease&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22law%2Einvention%22&quot;&gt;law.invention&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Prostate+cancer%22&quot;&gt;Prostate cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Bone+targeting%22&quot;&gt;Bone targeting&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trial%22&quot;&gt;Randomized controlled trial&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22law%22&quot;&gt;law&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Internal+medicine%22&quot;&gt;Internal medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Meta-analysis%22&quot;&gt;Meta-analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22medicine%22&quot;&gt;medicine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22External+beam+radiotherapy%22&quot;&gt;External beam radiotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Radio+isotopes%22&quot;&gt;Radio isotopes&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22business%22&quot;&gt;business&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => 352 Background: Among bone-targeted radio-isotopes (RI), Radium-223 (an α-emitter) is the only one with clearly demonstrated overall survival (OS) benefit in men with castration-resistant prostate cancer (CRPC). The aim of this meta-analysis is to estimate the OS impact of RI in men with CRPC. Methods: An individual patient data meta-analysis was carried out from randomized trials with inclusion period 1993-2013. Eligible trials included more than 50 patients, mandated bone metastases from CRPC and randomly evaluated RI. Endpoints were OS (primary), symptomatic skeletal events (SSE) and toxicity. A fixed-effect model was used. The log-rank test stratified by trial was used to estimate individual and overall hazard ratios (HR). Subset analyses were performed by the type of radiation (α vs. β emission) and by trial comparison: RI + Chemotherapy (CT) vs. CT, RI+ External beam radiotherapy (EBRT) vs. EBRT, RI vs. EBRT. Results: From 9 identified trials, data from 6 trials comprising 2081 patients (min: 64, max: 921) were collected with 2 trials representing 80% of data. The data from 3 trials (n = 341) were not available. The overall effect on OS favoured RI with HR = 0.86 [0.77-0.95] but high heterogeneity between trials (p &lt; 0.001, I2= 79.6%). The overall effect of α- emitters on OS (HR = 0.70 [0.58; 0.83], 2 trials, n = 985) significantly differed from that of β-emitters (HR = 0.96 [0.84; 1.10], n = 4 trials, n = 1096) (interaction p = 0.0041). The overall effect on SSE favoured RI with HR = 0.81 [0.69-0.93] (4 trials, n = 1806) with marked between trial heterogeneity (p = 0.08, I&#178; = 55.3%) and a significant difference (p = 0.02) by the type of RI (α-emitters: HR = 0.65 [0.52-0.82]-2 trials, β-emitters: HR = 0.93 [0.77-1.13]-2 trials). Conclusions: In men with metastatic CRPC a significant improvement of OS and SSE was obtained with bone targeted α-emitter radio isotopes, but not with β-emitter. However, some between trial heterogeneity of effects on OS need further investigations. )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1527-7755&lt;br /&gt;0732-183X )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => &lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://explore.openaire.eu/search/publication?articleId=doi_________::dafb509e72475258704096d825d8b0f4&quot; linkWindow=&quot;_blank&quot;&gt;https://explore.openaire.eu/search/publication?articleId=doi_________::dafb509e72475258704096d825d8b0f4&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://doi.org/10.1200/jco.2018.36.6_suppl.352&quot; linkWindow=&quot;_blank&quot;&gt;https://doi.org/10.1200/jco.2018.36.6_suppl.352&lt;/link&gt; )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi...........dafb509e72475258704096d825d8b0f4 )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 1 [StartPage] => 352 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Oncology [Type] => general ) [1] => Array ( [SubjectFull] => Cancer Research [Type] => general ) [2] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [3] => Array ( [SubjectFull] => Chemotherapy [Type] => general ) [4] => Array ( [SubjectFull] => business.industry [Type] => general ) [5] => Array ( [SubjectFull] => medicine.medical_treatment [Type] => general ) [6] => Array ( [SubjectFull] => Hazard ratio [Type] => general ) [7] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [8] => Array ( [SubjectFull] => law.invention [Type] => general ) [9] => Array ( [SubjectFull] => Prostate cancer [Type] => general ) [10] => Array ( [SubjectFull] => Bone targeting [Type] => general ) [11] => Array ( [SubjectFull] => Randomized controlled trial [Type] => general ) [12] => Array ( [SubjectFull] => law [Type] => general ) [13] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [14] => Array ( [SubjectFull] => Meta-analysis [Type] => general ) [15] => Array ( [SubjectFull] => medicine [Type] => general ) [16] => Array ( [SubjectFull] => External beam radiotherapy [Type] => general ) [17] => Array ( [SubjectFull] => Radio isotopes [Type] => general ) [18] => Array ( [SubjectFull] => business [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Karim Fizazi ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Laurence Collette ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jean-Pierre Pignon ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Chris Parker ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sigbjørn Smeland ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Safae Terrisse ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Karamouza Eleni ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => A. Oliver Sartor ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Gwénaël Le Teuff ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Nicholas D. James ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sarah Pirrie ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bertrand F. Tombal ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jad Chahoud ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bjørn Erisktein ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 20 [M] => 02 [Type] => published [Y] => 2018 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 15277755 ) [1] => Array ( [Type] => issn-print [Value] => 0732183X ) [2] => Array ( [Type] => issn-locals [Value] => edsair ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 36 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Journal of Clinical Oncology [Type] => main ) ) ) ) ) ) )
IllustrationInfo